

Media Coverage

Publication: *The Business Times Digital*

Date: 3 July 2026

Author: Elysia Tan

Boustead healthcare unit acquires majority stake in medtech company via S\$6 million equity injection

Post-acquisition, UroMedTech will continue to operate under its existing brand

[SINGAPORE] Boustead Singapore unit Boustead Medical Care Holdings (BMCH) has acquired a 60 per cent stake in a urology robotics company through a S\$6 million equity injection, the engineering and technology group said on Friday (Jul 3).

BMCH, which falls under Boustead's healthcare division, focuses on rehabilitation robotics, digital healthcare and medical innovation.

Singapore-based UroMedTech is known for pioneering robotic solutions for prostate cancer diagnosis through its UroMaster system. Its R&D road map includes integrating focal therapy treatment, a minimally invasive method to target tumours, within UroMaster.

Boustead said the investment will expand its healthcare technology portfolio into "the rapidly growing precision urology and oncology field, (while positioning) the group to capitalise on emerging trends in artificial intelligence-driven technology".

It added: "Through the acquisition, BMCH intends to accelerate the commercialisation of UroMaster, support the development of these next-generation capabilities, and expand UroMedTech's international presence by leveraging its regional distribution network, which includes public and private clinics and hospitals."

After the transaction is completed, UroMedTech will continue to operate under its existing brand and also work closely with BMCH to expand R&D, strengthen clinical partnerships and pursue regulatory approvals in key international markets.

The acquisition is part of BMCH's strategy to "secure long-term growth prospects through scalable, high-margin medical technology (platforms) with recurring revenue opportunities from consumables, software subscriptions and clinical services", Boustead said.

The deal is not expected to have a material impact on the group's profitability, earnings per share and tangible net asset value per share in the financial year ending Mar 31, 2027.

Boustead shares closed at S\$2.09 on Friday, up S\$0.05 or 2.5 per cent, before the announcement.